MyFinsight
Home
Blog
About
something is missing
$30,869K
Net proceeds from
issuance of common stock,...
$3K
Net cash provided by
financing activities
$909K
(-38.91%↓ Y/Y)
Canceled cashflow
$29,963K
Net change in cash
and cash...
-$13,798K
(23.96%↑ Y/Y)
Canceled cashflow
$909K
Stock-based compensation
$991K
(8.19%↑ Y/Y)
Amortization of operating
lease right-of-use...
$145K
(12.40%↑ Y/Y)
Depreciation and
amortization
$52K
(30.00%↑ Y/Y)
Proceeds from sale of
common stock under open...
-$29,710K
(-7583.63%↓ Y/Y)
Net proceeds from
sale of common stock...
-$157K
(-197.52%↓ Y/Y)
Repayment of notes payable
$96K
(6.67%↑ Y/Y)
Net cash used in
operating activities
-$14,707K
(21.96%↑ Y/Y)
Canceled cashflow
$1,188K
Net loss
-$13,030K
(13.68%↑ Y/Y)
Deferred revenue, net of
deferred contract...
-$1,457K
(-547.56%↓ Y/Y)
Prepaid expenses and
other current assets
$1,061K
(-45.37%↓ Y/Y)
Operating lease liability
-$165K
(-91.86%↓ Y/Y)
Accretion on marketable
securities
-$129K
(-3.20%↓ Y/Y)
Accounts payable and
accrued expenses
-$53K
(97.81%↑ Y/Y)
Back
Back
Cash Flow
Vistagen Therapeutics, Inc. (VTGN)
Vistagen Therapeutics, Inc. (VTGN)
source: myfinsight.com